# A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

> **NCT03022617** · PHASE4 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 12 (actual)

## Conditions studied

- Psoriatic Nail
- Psoriasis Vulgaris
- Psoriasis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT03022617
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2022-09-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03022617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03022617, "A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03022617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*